Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Contact Lenses | 14 | 2024 | 137 | 4.900 |
Why?
|
Cornea | 34 | 2024 | 1316 | 4.560 |
Why?
|
Corneal Diseases | 20 | 2022 | 535 | 4.160 |
Why?
|
Epithelium, Corneal | 7 | 2024 | 246 | 3.130 |
Why?
|
Cross-Linking Reagents | 10 | 2024 | 687 | 2.990 |
Why?
|
Keratoconus | 4 | 2023 | 112 | 2.110 |
Why?
|
Tears | 7 | 2024 | 254 | 2.030 |
Why?
|
Corneal Transplantation | 7 | 2023 | 315 | 1.920 |
Why?
|
Riboflavin | 6 | 2022 | 108 | 1.860 |
Why?
|
Photochemotherapy | 5 | 2018 | 826 | 1.720 |
Why?
|
Glaucoma | 8 | 2022 | 1194 | 1.670 |
Why?
|
Ophthalmic Solutions | 17 | 2024 | 312 | 1.650 |
Why?
|
Corneal Stroma | 6 | 2024 | 166 | 1.640 |
Why?
|
Drug Delivery Systems | 9 | 2024 | 2207 | 1.480 |
Why?
|
Keratitis | 4 | 2021 | 239 | 1.420 |
Why?
|
Collagen | 6 | 2022 | 2618 | 1.400 |
Why?
|
Myopia | 5 | 2021 | 254 | 1.240 |
Why?
|
Keratomileusis, Laser In Situ | 4 | 2015 | 81 | 1.210 |
Why?
|
Photosensitizing Agents | 7 | 2022 | 625 | 1.190 |
Why?
|
Contact Lenses, Hydrophilic | 3 | 2015 | 53 | 1.160 |
Why?
|
Corneal Topography | 5 | 2022 | 69 | 1.130 |
Why?
|
Descemet Stripping Endothelial Keratoplasty | 3 | 2022 | 110 | 1.030 |
Why?
|
Nerve Growth Factor | 2 | 2024 | 155 | 1.000 |
Why?
|
Conjunctivitis, Allergic | 5 | 2023 | 124 | 0.980 |
Why?
|
Artificial Organs | 6 | 2017 | 149 | 0.980 |
Why?
|
Prostaglandins F, Synthetic | 2 | 2016 | 32 | 0.980 |
Why?
|
Myofibroblasts | 3 | 2024 | 229 | 0.970 |
Why?
|
Ultraviolet Rays | 7 | 2024 | 1102 | 0.910 |
Why?
|
Corneal Edema | 1 | 2024 | 45 | 0.870 |
Why?
|
Prostheses and Implants | 8 | 2022 | 1273 | 0.860 |
Why?
|
Chitosan | 1 | 2024 | 138 | 0.820 |
Why?
|
Rabbits | 8 | 2024 | 4734 | 0.820 |
Why?
|
Bioprosthesis | 3 | 2015 | 589 | 0.790 |
Why?
|
Corneal Opacity | 1 | 2022 | 52 | 0.760 |
Why?
|
Intraocular Pressure | 4 | 2021 | 1304 | 0.750 |
Why?
|
Dry Eye Syndromes | 5 | 2023 | 384 | 0.730 |
Why?
|
Keratoplasty, Penetrating | 7 | 2023 | 143 | 0.730 |
Why?
|
Macular Degeneration | 2 | 2021 | 1014 | 0.710 |
Why?
|
Retinal Neoplasms | 1 | 2022 | 147 | 0.700 |
Why?
|
Eye Diseases | 4 | 2021 | 659 | 0.690 |
Why?
|
Fibroblasts | 5 | 2024 | 4159 | 0.670 |
Why?
|
Conjunctival Diseases | 2 | 2018 | 109 | 0.670 |
Why?
|
Retinoblastoma | 1 | 2022 | 316 | 0.660 |
Why?
|
Azepines | 1 | 2021 | 327 | 0.650 |
Why?
|
Fluoroquinolones | 1 | 2021 | 307 | 0.650 |
Why?
|
Orthokeratologic Procedures | 1 | 2018 | 6 | 0.630 |
Why?
|
Cytological Techniques | 1 | 2020 | 220 | 0.620 |
Why?
|
Hydrogels | 1 | 2024 | 728 | 0.610 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2021 | 1526 | 0.580 |
Why?
|
Macular Edema | 1 | 2022 | 387 | 0.580 |
Why?
|
Lasers, Excimer | 3 | 2021 | 68 | 0.570 |
Why?
|
Adrenergic alpha-2 Receptor Agonists | 1 | 2018 | 90 | 0.560 |
Why?
|
Cell Communication | 2 | 2021 | 1660 | 0.540 |
Why?
|
Hyperemia | 1 | 2018 | 224 | 0.530 |
Why?
|
Pharmaceutical Preparations | 2 | 2015 | 1084 | 0.530 |
Why?
|
Uveitis | 1 | 2020 | 398 | 0.530 |
Why?
|
Rose Bengal | 1 | 2016 | 115 | 0.510 |
Why?
|
Porphyrins | 1 | 2018 | 351 | 0.500 |
Why?
|
Proteomics | 3 | 2024 | 3910 | 0.490 |
Why?
|
Eye Infections, Parasitic | 3 | 2024 | 27 | 0.490 |
Why?
|
Light | 2 | 2023 | 1365 | 0.490 |
Why?
|
Conjunctivitis, Bacterial | 1 | 2015 | 22 | 0.490 |
Why?
|
Dexamethasone | 2 | 2021 | 1963 | 0.490 |
Why?
|
Tandem Mass Spectrometry | 1 | 2021 | 1192 | 0.480 |
Why?
|
Drug Carriers | 2 | 2021 | 700 | 0.470 |
Why?
|
Prosthesis Implantation | 4 | 2013 | 595 | 0.470 |
Why?
|
Cyclosporine | 3 | 2023 | 778 | 0.460 |
Why?
|
Focal Infection, Dental | 1 | 2014 | 27 | 0.460 |
Why?
|
Coated Materials, Biocompatible | 1 | 2016 | 314 | 0.450 |
Why?
|
Visual Prosthesis | 1 | 2015 | 49 | 0.450 |
Why?
|
RNA | 1 | 2024 | 2717 | 0.450 |
Why?
|
Photorefractive Keratectomy | 2 | 2021 | 34 | 0.450 |
Why?
|
Mite Infestations | 2 | 2024 | 10 | 0.440 |
Why?
|
Blepharitis | 2 | 2024 | 37 | 0.430 |
Why?
|
Fluorescein | 4 | 2023 | 176 | 0.430 |
Why?
|
Staphylococcal Skin Infections | 1 | 2014 | 77 | 0.430 |
Why?
|
Lenses, Intraocular | 1 | 2015 | 141 | 0.430 |
Why?
|
Ophthalmology | 3 | 2015 | 561 | 0.420 |
Why?
|
Retinal Diseases | 2 | 2018 | 709 | 0.410 |
Why?
|
Biosensing Techniques | 1 | 2018 | 642 | 0.400 |
Why?
|
Diabetic Retinopathy | 1 | 2022 | 1299 | 0.400 |
Why?
|
Biocompatible Materials | 5 | 2022 | 1682 | 0.390 |
Why?
|
Econazole | 1 | 2011 | 4 | 0.380 |
Why?
|
Dilatation, Pathologic | 3 | 2022 | 527 | 0.380 |
Why?
|
Wound Healing | 6 | 2024 | 2792 | 0.380 |
Why?
|
Limbus Corneae | 2 | 2024 | 144 | 0.360 |
Why?
|
Mesenchymal Stem Cells | 1 | 2021 | 1663 | 0.350 |
Why?
|
Humans | 80 | 2024 | 765968 | 0.350 |
Why?
|
Postoperative Complications | 7 | 2021 | 15747 | 0.340 |
Why?
|
Cytokines | 2 | 2024 | 7421 | 0.340 |
Why?
|
Benzimidazoles | 3 | 2023 | 864 | 0.320 |
Why?
|
Reimbursement Mechanisms | 1 | 2015 | 672 | 0.320 |
Why?
|
Lacrimal Duct Obstruction | 1 | 2009 | 53 | 0.310 |
Why?
|
Delayed-Action Preparations | 3 | 2019 | 967 | 0.310 |
Why?
|
Diagnostic Techniques, Ophthalmological | 2 | 2008 | 252 | 0.310 |
Why?
|
Coculture Techniques | 2 | 2024 | 1336 | 0.310 |
Why?
|
Administration, Topical | 4 | 2019 | 704 | 0.310 |
Why?
|
Cell Proliferation | 1 | 2024 | 10429 | 0.300 |
Why?
|
Candida albicans | 1 | 2011 | 377 | 0.300 |
Why?
|
Cosmetics | 1 | 2009 | 102 | 0.300 |
Why?
|
Refractive Errors | 2 | 2021 | 148 | 0.300 |
Why?
|
Drug Approval | 1 | 2015 | 818 | 0.290 |
Why?
|
Steroids | 3 | 2022 | 933 | 0.290 |
Why?
|
Endothelial Cells | 1 | 2020 | 3584 | 0.290 |
Why?
|
Cells, Cultured | 5 | 2024 | 18973 | 0.280 |
Why?
|
Cell Differentiation | 2 | 2021 | 11641 | 0.270 |
Why?
|
Mites | 2 | 2024 | 46 | 0.270 |
Why?
|
Ciprofloxacin | 1 | 2009 | 314 | 0.270 |
Why?
|
Eyelashes | 2 | 2024 | 20 | 0.270 |
Why?
|
Corneal Neovascularization | 2 | 2022 | 184 | 0.260 |
Why?
|
Anthropometry | 2 | 2008 | 1338 | 0.260 |
Why?
|
Surgical Flaps | 1 | 2015 | 1677 | 0.260 |
Why?
|
Antifungal Agents | 1 | 2011 | 769 | 0.260 |
Why?
|
Piperidines | 3 | 2023 | 1664 | 0.260 |
Why?
|
Ocular Hypertension | 2 | 2018 | 211 | 0.260 |
Why?
|
Anti-Bacterial Agents | 3 | 2021 | 7478 | 0.260 |
Why?
|
Microscopy, Confocal | 3 | 2024 | 1966 | 0.250 |
Why?
|
Cicatrix | 2 | 2022 | 798 | 0.250 |
Why?
|
Epithelial Cells | 3 | 2022 | 3681 | 0.230 |
Why?
|
Acanthamoeba Keratitis | 1 | 2024 | 14 | 0.230 |
Why?
|
Photography | 1 | 2007 | 533 | 0.230 |
Why?
|
Mucin 5AC | 1 | 2024 | 96 | 0.230 |
Why?
|
Methacrylates | 1 | 2024 | 109 | 0.230 |
Why?
|
Graft Rejection | 3 | 2014 | 4499 | 0.230 |
Why?
|
Asthenopia | 1 | 2023 | 12 | 0.220 |
Why?
|
Basketball | 1 | 2003 | 43 | 0.210 |
Why?
|
Graft Survival | 3 | 2013 | 3890 | 0.210 |
Why?
|
Anti-Allergic Agents | 2 | 2022 | 153 | 0.200 |
Why?
|
Optic Nerve Injuries | 1 | 2003 | 150 | 0.200 |
Why?
|
Immunosuppressive Agents | 3 | 2021 | 4209 | 0.190 |
Why?
|
Prednisolone | 1 | 2022 | 324 | 0.190 |
Why?
|
Double-Blind Method | 9 | 2023 | 12437 | 0.190 |
Why?
|
Presbyopia | 1 | 2021 | 10 | 0.190 |
Why?
|
Anti-Infective Agents | 1 | 2009 | 986 | 0.180 |
Why?
|
Achromobacter | 1 | 2021 | 8 | 0.180 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2021 | 182 | 0.180 |
Why?
|
Cell Movement | 2 | 2024 | 5194 | 0.180 |
Why?
|
Aqueous Humor | 1 | 2021 | 152 | 0.180 |
Why?
|
Eye Proteins | 1 | 2024 | 628 | 0.180 |
Why?
|
Staphylococcus aureus | 1 | 2009 | 1424 | 0.180 |
Why?
|
Limit of Detection | 1 | 2021 | 272 | 0.180 |
Why?
|
Computers | 1 | 2023 | 588 | 0.180 |
Why?
|
Attitude of Health Personnel | 1 | 2014 | 3925 | 0.170 |
Why?
|
Polyhydroxyethyl Methacrylate | 2 | 2011 | 30 | 0.170 |
Why?
|
Middle Aged | 30 | 2024 | 223009 | 0.170 |
Why?
|
Visual Acuity | 5 | 2021 | 2708 | 0.170 |
Why?
|
Disease Models, Animal | 4 | 2023 | 18293 | 0.170 |
Why?
|
Organ Preservation Solutions | 1 | 2021 | 105 | 0.170 |
Why?
|
Acute Disease | 3 | 2024 | 7232 | 0.170 |
Why?
|
Corneal Ulcer | 2 | 2011 | 125 | 0.170 |
Why?
|
Animals | 13 | 2024 | 168764 | 0.170 |
Why?
|
Follow-Up Studies | 12 | 2024 | 39193 | 0.170 |
Why?
|
Eye | 2 | 2021 | 710 | 0.170 |
Why?
|
Iron Chelating Agents | 1 | 2021 | 142 | 0.170 |
Why?
|
Drug Contamination | 1 | 2021 | 152 | 0.160 |
Why?
|
Guaifenesin | 1 | 2019 | 5 | 0.160 |
Why?
|
Posterior Eye Segment | 1 | 2019 | 18 | 0.160 |
Why?
|
Culture Media, Conditioned | 1 | 2020 | 522 | 0.160 |
Why?
|
Male | 34 | 2024 | 363698 | 0.160 |
Why?
|
Retrospective Studies | 13 | 2024 | 81514 | 0.160 |
Why?
|
Fluorescence | 1 | 2021 | 753 | 0.160 |
Why?
|
Stromal Cells | 1 | 2024 | 1329 | 0.160 |
Why?
|
Fuchs' Endothelial Dystrophy | 1 | 2021 | 103 | 0.160 |
Why?
|
Polyglycolic Acid | 2 | 2011 | 406 | 0.150 |
Why?
|
Conjunctiva | 2 | 2021 | 477 | 0.150 |
Why?
|
Bibliometrics | 1 | 2022 | 357 | 0.150 |
Why?
|
Microscopy, Electron, Scanning | 2 | 2011 | 939 | 0.150 |
Why?
|
Tight Junctions | 1 | 2020 | 330 | 0.150 |
Why?
|
Female | 34 | 2024 | 396112 | 0.140 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2021 | 637 | 0.140 |
Why?
|
Retina | 2 | 2019 | 2657 | 0.140 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2019 | 10729 | 0.140 |
Why?
|
Tissue Donors | 3 | 2021 | 2395 | 0.140 |
Why?
|
Ultrasonography | 2 | 2007 | 5993 | 0.140 |
Why?
|
Combined Modality Therapy | 2 | 2022 | 8529 | 0.140 |
Why?
|
Cataract Extraction | 2 | 2015 | 464 | 0.140 |
Why?
|
Tensile Strength | 1 | 2018 | 332 | 0.140 |
Why?
|
Prospective Studies | 16 | 2023 | 54802 | 0.140 |
Why?
|
Burns, Chemical | 1 | 2018 | 123 | 0.140 |
Why?
|
Antihypertensive Agents | 2 | 2017 | 2033 | 0.140 |
Why?
|
Medicare | 1 | 2015 | 6823 | 0.130 |
Why?
|
United States Food and Drug Administration | 2 | 2015 | 1672 | 0.130 |
Why?
|
Replantation | 1 | 2017 | 146 | 0.130 |
Why?
|
Chemistry, Pharmaceutical | 2 | 2014 | 272 | 0.130 |
Why?
|
Fibronectins | 1 | 2020 | 719 | 0.130 |
Why?
|
Pruritus | 2 | 2022 | 378 | 0.130 |
Why?
|
Equipment Design | 2 | 2016 | 3481 | 0.130 |
Why?
|
Fluorescent Dyes | 3 | 2021 | 1930 | 0.130 |
Why?
|
Tonometry, Ocular | 1 | 2016 | 238 | 0.120 |
Why?
|
Cryopreservation | 1 | 2020 | 728 | 0.120 |
Why?
|
Anterior Eye Segment | 1 | 2016 | 144 | 0.120 |
Why?
|
Prosthesis Fitting | 1 | 2015 | 74 | 0.120 |
Why?
|
Vision Disorders | 2 | 2015 | 1087 | 0.120 |
Why?
|
Inflammation | 3 | 2022 | 10850 | 0.120 |
Why?
|
Cell Separation | 1 | 2020 | 1718 | 0.120 |
Why?
|
Prosthesis Design | 4 | 2011 | 2105 | 0.120 |
Why?
|
Fibrosis | 1 | 2022 | 2070 | 0.120 |
Why?
|
Lactic Acid | 2 | 2011 | 1137 | 0.120 |
Why?
|
Glaucoma, Open-Angle | 1 | 2021 | 742 | 0.120 |
Why?
|
Methylprednisolone | 1 | 2016 | 386 | 0.120 |
Why?
|
Recombinant Proteins | 1 | 2024 | 6493 | 0.120 |
Why?
|
beta-Lactamases | 1 | 2016 | 308 | 0.120 |
Why?
|
Proteome | 1 | 2024 | 1899 | 0.110 |
Why?
|
Technology, Pharmaceutical | 1 | 2014 | 83 | 0.110 |
Why?
|
Adult | 23 | 2024 | 223044 | 0.110 |
Why?
|
Macaca fascicularis | 1 | 2016 | 907 | 0.110 |
Why?
|
Actins | 1 | 2021 | 2056 | 0.110 |
Why?
|
Educational Measurement | 2 | 2015 | 1260 | 0.110 |
Why?
|
Collagenases | 1 | 2014 | 221 | 0.110 |
Why?
|
Propoxycaine | 1 | 2013 | 6 | 0.110 |
Why?
|
Eye Infections, Bacterial | 1 | 2016 | 239 | 0.110 |
Why?
|
Fluorescein Angiography | 1 | 2019 | 1085 | 0.110 |
Why?
|
Preservatives, Pharmaceutical | 2 | 2023 | 34 | 0.110 |
Why?
|
Aged | 18 | 2024 | 171117 | 0.110 |
Why?
|
Polymethyl Methacrylate | 2 | 2011 | 126 | 0.110 |
Why?
|
Device Approval | 1 | 2015 | 164 | 0.110 |
Why?
|
Drug Stability | 1 | 2013 | 288 | 0.100 |
Why?
|
Elasticity | 1 | 2015 | 652 | 0.100 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2013 | 169 | 0.100 |
Why?
|
Escherichia coli Infections | 1 | 2016 | 519 | 0.100 |
Why?
|
Benzazepines | 1 | 2014 | 308 | 0.100 |
Why?
|
Sodium Channel Blockers | 1 | 2013 | 170 | 0.100 |
Why?
|
Iron | 1 | 2021 | 1816 | 0.100 |
Why?
|
Tetrodotoxin | 1 | 2013 | 244 | 0.100 |
Why?
|
Tacrolimus | 1 | 2016 | 753 | 0.100 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2016 | 592 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2022 | 3513 | 0.100 |
Why?
|
Glucocorticoids | 1 | 2021 | 2132 | 0.100 |
Why?
|
Desiccation | 1 | 2011 | 77 | 0.090 |
Why?
|
Ophthalmic Nerve | 1 | 2011 | 43 | 0.090 |
Why?
|
Eye Banks | 2 | 2021 | 40 | 0.090 |
Why?
|
Anesthesia, Local | 1 | 2013 | 276 | 0.090 |
Why?
|
Eye Infections | 1 | 2011 | 63 | 0.090 |
Why?
|
Monitoring, Physiologic | 1 | 2018 | 1792 | 0.090 |
Why?
|
Young Adult | 10 | 2024 | 59889 | 0.090 |
Why?
|
Anti-Inflammatory Agents | 2 | 2018 | 1808 | 0.080 |
Why?
|
Costs and Cost Analysis | 1 | 2015 | 1668 | 0.080 |
Why?
|
Refraction, Ocular | 2 | 2021 | 188 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2659 | 0.080 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 660 | 0.080 |
Why?
|
Autoimmune Diseases | 1 | 2021 | 2226 | 0.080 |
Why?
|
Spectrum Analysis, Raman | 1 | 2011 | 252 | 0.080 |
Why?
|
Imidazoles | 1 | 2014 | 1162 | 0.080 |
Why?
|
Angiogenesis Inhibitors | 2 | 2022 | 2056 | 0.080 |
Why?
|
Titanium | 1 | 2011 | 490 | 0.070 |
Why?
|
Treatment Outcome | 11 | 2024 | 65188 | 0.070 |
Why?
|
Body Weights and Measures | 1 | 2008 | 208 | 0.070 |
Why?
|
Aged, 80 and over | 10 | 2024 | 59489 | 0.070 |
Why?
|
Allergens | 1 | 2014 | 1436 | 0.070 |
Why?
|
Glucose | 1 | 2018 | 4335 | 0.070 |
Why?
|
Anesthetics, Local | 1 | 2013 | 1015 | 0.070 |
Why?
|
Quality of Life | 3 | 2023 | 13462 | 0.060 |
Why?
|
Intraoperative Complications | 1 | 2013 | 1162 | 0.060 |
Why?
|
United States | 4 | 2022 | 72903 | 0.060 |
Why?
|
Clinical Competence | 2 | 2015 | 4863 | 0.060 |
Why?
|
Cross-Sectional Studies | 3 | 2022 | 26318 | 0.060 |
Why?
|
Escherichia coli | 1 | 2016 | 4214 | 0.060 |
Why?
|
Eye Protective Devices | 1 | 2003 | 32 | 0.050 |
Why?
|
Graft vs Host Disease | 1 | 2016 | 3078 | 0.050 |
Why?
|
Ketotifen | 1 | 2023 | 24 | 0.050 |
Why?
|
Tomography, Optical Coherence | 1 | 2016 | 2932 | 0.050 |
Why?
|
Sulfonamides | 1 | 2013 | 1984 | 0.050 |
Why?
|
Thrombospondin 1 | 1 | 2024 | 256 | 0.050 |
Why?
|
Cell Count | 2 | 2021 | 1823 | 0.050 |
Why?
|
Medication Adherence | 1 | 2014 | 2192 | 0.050 |
Why?
|
Child | 4 | 2022 | 80564 | 0.050 |
Why?
|
Adolescent | 7 | 2023 | 88835 | 0.050 |
Why?
|
Postoperative Period | 1 | 2007 | 1816 | 0.050 |
Why?
|
Risk Factors | 5 | 2022 | 74840 | 0.050 |
Why?
|
Microbial Sensitivity Tests | 2 | 2021 | 1971 | 0.050 |
Why?
|
Rodentia | 1 | 2023 | 261 | 0.050 |
Why?
|
Erythema | 1 | 2023 | 262 | 0.050 |
Why?
|
Decision Making | 1 | 2015 | 3965 | 0.050 |
Why?
|
Statistics as Topic | 1 | 2007 | 2352 | 0.050 |
Why?
|
Corneal Endothelial Cell Loss | 1 | 2021 | 24 | 0.050 |
Why?
|
Internship and Residency | 2 | 2015 | 5946 | 0.050 |
Why?
|
Reference Values | 1 | 2008 | 4908 | 0.040 |
Why?
|
Pyrimidines | 1 | 2013 | 3047 | 0.040 |
Why?
|
Meibomian Glands | 1 | 2020 | 74 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2024 | 12240 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2018 | 5891 | 0.040 |
Why?
|
Dendritic Cells | 1 | 2011 | 2747 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2014 | 4058 | 0.040 |
Why?
|
DNA, Ribosomal | 1 | 2021 | 300 | 0.040 |
Why?
|
Bacteriological Techniques | 1 | 2021 | 276 | 0.040 |
Why?
|
Expectorants | 1 | 2019 | 22 | 0.040 |
Why?
|
Donor Selection | 1 | 2021 | 242 | 0.040 |
Why?
|
Eyelid Diseases | 1 | 2020 | 155 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 10383 | 0.040 |
Why?
|
Drug Compounding | 1 | 2019 | 235 | 0.040 |
Why?
|
Tissue and Organ Harvesting | 1 | 2021 | 373 | 0.040 |
Why?
|
Sickness Impact Profile | 1 | 2019 | 297 | 0.040 |
Why?
|
Keratoconjunctivitis Sicca | 1 | 2017 | 26 | 0.040 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 2018 | 93 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5508 | 0.030 |
Why?
|
Staining and Labeling | 1 | 2021 | 1072 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2021 | 1043 | 0.030 |
Why?
|
Drug Implants | 1 | 2017 | 230 | 0.030 |
Why?
|
Water | 1 | 2021 | 1417 | 0.030 |
Why?
|
Intravitreal Injections | 1 | 2017 | 401 | 0.030 |
Why?
|
Time Factors | 3 | 2013 | 40065 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2009 | 12976 | 0.030 |
Why?
|
Anesthetics, Combined | 1 | 2013 | 43 | 0.030 |
Why?
|
Cohort Studies | 2 | 2013 | 41649 | 0.030 |
Why?
|
Virulence | 1 | 2016 | 1289 | 0.030 |
Why?
|
Quaternary Ammonium Compounds | 1 | 2013 | 204 | 0.030 |
Why?
|
Equipment Contamination | 1 | 2013 | 183 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2007 | 20124 | 0.020 |
Why?
|
Membranes | 1 | 2012 | 164 | 0.020 |
Why?
|
Neuroprotective Agents | 1 | 2018 | 959 | 0.020 |
Why?
|
Indazoles | 1 | 2013 | 303 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 4015 | 0.020 |
Why?
|
Phagocytosis | 1 | 2016 | 1520 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2024 | 3446 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2014 | 962 | 0.020 |
Why?
|
Nervous System | 1 | 2011 | 542 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2011 | 1589 | 0.020 |
Why?
|
Focus Groups | 1 | 2013 | 1459 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2018 | 4348 | 0.020 |
Why?
|
Ophthalmologic Surgical Procedures | 1 | 2009 | 354 | 0.020 |
Why?
|
Immune System | 1 | 2011 | 799 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8733 | 0.020 |
Why?
|
Reoperation | 1 | 2015 | 4294 | 0.020 |
Why?
|
Glaucoma Drainage Implants | 1 | 2006 | 107 | 0.020 |
Why?
|
Trabeculectomy | 1 | 2006 | 174 | 0.010 |
Why?
|
Prevalence | 1 | 2021 | 15842 | 0.010 |
Why?
|
Incidence | 1 | 2022 | 21480 | 0.010 |
Why?
|
Quality-Adjusted Life Years | 1 | 2009 | 1737 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3230 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2013 | 8102 | 0.010 |
Why?
|
Feedback | 1 | 2005 | 796 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 8041 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2013 | 3475 | 0.010 |
Why?
|
Cell Line | 1 | 2013 | 15543 | 0.010 |
Why?
|
Teaching | 1 | 2005 | 1169 | 0.010 |
Why?
|
Rats | 1 | 2013 | 23707 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2009 | 5526 | 0.010 |
Why?
|
Education, Medical, Graduate | 1 | 2005 | 2418 | 0.010 |
Why?
|
Curriculum | 1 | 2005 | 3782 | 0.010 |
Why?
|
Databases, Factual | 1 | 2005 | 8067 | 0.010 |
Why?
|